Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 18/20 | 0.44 |
| ▸ | MMP13 | P45452 | 15/20 | 0.44 |
| ▸ | MMP9 | P14780 | 14/20 | 0.44 |
| ▸ | MMP1 | P03956 | 13/20 | 0.44 |
| ▸ | MMP2 | P08253 | 4/20 | 0.44 |
| ▸ | MMP8 | P22894 | 4/20 | 0.44 |
| ▸ | MMP7 | P09237 | 3/20 | 0.44 |
| ▸ | MMP14 | P50281 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657188 | 0.87 | ADAM17 (0.44) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6408312 | 0.85 | ADAM17 (0.43) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL5661150 | 0.85 | ADAM17 (0.43) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL6407732 | 0.81 | CA12 (0.46) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL5657792 | 0.80 | ADAM17 (0.63) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL5658080 | 0.78 | ALDH1A1 (0.47) | — | |
| SCHEMBL8044163 | 0.69 | ADAM17 (0.47) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL487316 | 0.69 | ALDH1A1 (0.50) | — | |
| SCHEMBL1793387 | 0.68 | PKM (0.58) | ADAM17MMP13MMP9MMP1MMP2 | |
| SCHEMBL7369630 | 0.67 | TSHR (0.68) | MMP13MMP1MMP2MMP14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272928-A1 | Method for preparing hydroxamic acids | WYETH (US) | 2005-12-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272928-A1 | Method for preparing hydroxamic acids | H1-5, HDAC5, PGA5 | ADAM17 687/4885MMP13 389/4885MMP9 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.